T he type 1 angiotensin receptor (AT 1 R) is a key component of the renin-angiotensin system. AT 1 R mediates most of the classically recognized actions of angiotensin II. Activation of AT 1 Rs stimulates vascular contractility and renal sodium retention 1-4 playing a crucial role in regulating blood pressure in health and disease. In addition to these hemodynamic effects, the AT 1 R also mediates cell proliferation, fibrosis, and end organ damage. [5][6][7] Because of the key role of these receptors in physiology and pathophysiology, accurate detection of the AT 1 R protein is paramount for investigations aimed at understanding molecular mechanisms of health and disease. Although several AT 1 R antibodies are available commercially we, and others, 8 had major concerns about their specificity. Humans have only 1 AT 1 R isoform; however, 2 isoforms exist in rodents, termed AT 1A and AT 1B . These receptor subtypes are products of 2 different genes: Agtr1a is located on mouse chromosome 13 (17 in rats), and Agtr1b on mouse chromosome 3 (2 in rats). They both encode a 375-amino acid protein with a predicted molecular weight of 42 kDa.
T he type 1 angiotensin receptor (AT 1 R) is a key component of the renin-angiotensin system. AT 1 R mediates most of the classically recognized actions of angiotensin II. Activation of AT 1 Rs stimulates vascular contractility and renal sodium retention [1] [2] [3] [4] playing a crucial role in regulating blood pressure in health and disease. In addition to these hemodynamic effects, the AT 1 R also mediates cell proliferation, fibrosis, and end organ damage. [5] [6] [7] Because of the key role of these receptors in physiology and pathophysiology, accurate detection of the AT 1 R protein is paramount for investigations aimed at understanding molecular mechanisms of health and disease. Although several AT 1 R antibodies are available commercially we, and others, 8 had major concerns about their specificity. Humans have only 1 AT 1 R isoform; however, 2 isoforms exist in rodents, termed AT 1A and AT 1B . These receptor subtypes are products of 2 different genes: Agtr1a is located on mouse chromosome 13 (17 in rats), and Agtr1b on mouse chromosome 3 (2 in rats). They both encode a 375-amino acid protein with a predicted molecular weight of 42 kDa. [9] [10] [11] They share 94% identity and are indistinguishable pharmacologically. Based on bioinformatics predictions (http://www.cbs.
dtu.dk/services/NetNGlyc/), these receptors are presumed to undergo post-translational glycosylation. Accordingly, using a plasmid expressing the AT 1 R tagged to a myc epitope, Deslauriers and colleagues reported massive AT 1 R glycosylation in transfected COS-7 cells. 12 In that study, the molecular size of the glycosylated AT 1 R form was estimated to be ≈100 to 150 kDa. Although the degree of glycosylation of proteins is a tissue-specific process, it is difficult to predict the molecular mass of these receptors under different tissues or experimental conditions, and published data clarifying this issue are lacking.
During the last decade, anti-AT 1 R antibodies have been widely used in scientific reports related to AT 1 R signaling and functions. However, their specificity has not been thoroughly investigated in the medical literature. In preliminary studies using mice with targeted deletion of AT 1 R genes that were generated in our laboratory, we became concerned about the specificity of these antibodies. Accordingly, we carried out a systematic evaluation of a panel of anti-AT 1 R antibodies that were purchased from commercial vendors, focusing on their utility and specificity for Western blot analysis and immunohistochemistry.
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Results
We first performed Western blot analysis using homogenates of cortex (C) and medulla (M) from kidneys of wild-type (WT) mice comparing band patterns produced by 3 anti-AT 1 R antibodies. As shown in Figure 1 , antibodies 1 and 2 each generated a single band between 38 and 48 kDa, which would be around the expected 41-kDa size of the AT 1 R. [9] [10] [11] Although each of these antibodies identified a single band, the molecular weight of these bands was slightly different. In contrast, antibody 3 produced multiple bands of a broad range of sizes (Figure 1; n=3) . Between the 3 antibodies, the patterns of reactivity were very different with no common bands seen within the predicted molecular size range for the AT 1 R.
To test the specificity of each antibody for the AT 1 R, we performed additional Western blot analyses but now using protein homogenates from kidneys of mice genetically deficient in 1 or both AT 1 R subtypes. As shown in Figure 2 , there were no apparent differences in the pattern of reactivity of each of the antibodies between protein extracts of kidneys from WT mice, compared with those from mice lacking the major AT 1 R isoform, AT 1A R (AT 1A KO). Furthermore, the patterns of antibody reactivity were virtually identical in the kidneys from WT and AT 1AB KO (Figure 2 ; n=3). To be certain that we were not missing a band corresponding to AT 1 R protein that was obscured or low abundance, we overexposed the X-ray film to the membrane for up to 60 minutes, but did not detect additional bands.
We also tested the polyclonal AT 1 R antibody 2 for immunohistochemical staining. As shown in Figure 3A -3B, tissue sections from WT kidney in the absence ( Figure 3A ) of primary antibody demonstrate minimal background staining compared with sections incubated with the AT 1 R antibody ( Figure 3B To verify that the AT 1 R knockout mice used in the studies were truly deficient in receptors, we measured AT 1 R expression and functional responses to angiotensin II. By quantitative real-time-polymerase chain reaction, AT 1A mRNA receptor abundance in WT kidneys was similar in the cortex and medulla (10.7±0.4 and 12.5±1.5 arbitrary units for cortex and medulla, n=4; n.s.). In contrast, AT 1A receptor transcript was undetectable in either cortex or medulla of both AT 1A KO and AT 1AB KO kidneys ( Figure 4A ). Additionally, AT 1B receptor mRNA was detected in adrenal glands from WTs and AT 1A KO but undetectable in AT 1AB KO ( Figure 4B ). Furthermore, to confirm physiological absence of functional AT 1 R in the knockouts, we tested the ability of angiotensin II to cause acute increases in blood pressure. Bolus infusions of 10 μg/ kg angiotensin II increased blood pressure by 34±4 mm Hg in WT mice. However, this response was significantly blunted in AT 1A KO and completely absent in AT 1AB KO mice (change: 4±1 and 0.5±0.8 mm Hg for AT 1A KO and AT 1AB KO; P<0.001 versus WTs, n=3-4; Figure 4C ). These experiments confirm the lack of each AT 1 R subtype expression and activity in our knockout mouse lines and indicate that the anomalous results obtained by Western blotting and immunohistochemistry are likely a result of antibodies cross-reacting with unknown proteins other than the AT 1 R. To explore the possibility that the lack of specificity of anti-AT 1 R antibodies was attributable to insufficient sensitivity, we overexpressed the AT 1 R in human embryonic kidney (HEK) cells by transfecting them with DNA encoding the mouse AT 1A R. To verify appropriate targeting of the AT 1 R protein to the plasma membrane, we used a plasmid encoding the AT 1A receptor fused with the mCherry fluorescence protein (AT 1A -mCherry) and imaged the receptor by live cell-fluorescence confocal microscopy. We found that, after 24 hours of transfection, a significant amount of the total AT 1A R pool was present at the plasma membrane ( Figure 5A, I ). In addition, we also observed that the nonplasma membrane-associated AT 1A R pool does not colocalize with the endoplasmic reticulum-associated protein Calreticulin ( Figure 5A , II and III), but it partially colocalizes with the trans-Golgi network-associated protein GalNac-T ( Figure 5A , IV-VI).
We next tested the ability of the commercial antibodies to detect AT 1A R increments at different levels of over-expression. For this, we subcloned the AT 1A R sequence from plasmid AT 1A -mCherry into the pcDNA3.1 His vector in frame with the His epitope (AT 1A -His), and different amounts of plasmidic DNA were transfected into HEK cells. For detection of the exogenous His-tagged proteins by Western blot, an anti-His antibody was used. The anti-His antibody detected multiple bands close to 39 kDa in cells transfected with 2 μg plasmid. The intensity of these bands (relative to GAPDH) increased by 83±40% and 193±39% (n=3) in cells transfected with 4 and 8 μg DNA (lower red box on Figure 5B ). In contrast, this pattern was not reproduced by utilizing any of the anti-AT 1 R antibodies ( Figure 5B ).
Discussion
In this study, we tested 3 different rabbit polyclonal commercial antibodies that have been used in published reports to detect AT 1 R protein. Antibodies 1 and 2 were raised against a short sequence (15 amino acids) of the extracellular amino terminus of the AT 1 R protein that is identical among rat and mouse. This region is ≈95% identical between AT 1A and AT 1B receptors (accession numbers NP_796296.1 and EDL34899.1). Antibody 3 was raised against intracellular carboxy terminus sequences also identical between rat and mouse. In this case, 2 synthetic peptides specific for each receptor subtype, AT 1A and AT 1B , were used. The AT 1A and AT 1B receptors are each 359 amino acids, highly homologous (sharing <94% amino acid identity) with predicted molecular masses of 41 kDa. Therefore, the antibodies used in these studies should not distinguish AT 1A and AT 1B receptor subtypes. Although both AT 1 R isoforms undergo post-translational glycosylation, a single ≈41 kDa band should represent the nonglycosylated AT 1A or AT 1B receptor, whereas higher molecular bands would be expected for the glycosylated forms. 12 By performing direct side-by-side comparisons of the bands recognized by each antibody, we concluded that each antibody binds to distinct unknown proteins of diverse molecular sizes and raised the concern that these antibodies cross-react with proteins other than the AT 1 R. Experiments using kidney tissue from mice with genetic deficiencies of the major murine AT 1 R isoform (AT 1A ) revealed that all 3 antibodies showed the same pattern of bands on Western blots whether the proteins were derived from WT or AT 1A KO mice. Similar findings using the single AT 1A KO were recently reported. 12a Inclusion of samples from the double knockout (AT 1AB KO) eliminated the possibility that the positive signal in the AT 1A KO was attributable to upregulation of the homologous AT 1B R. This suggests that none of these antibodies recognize the AT 1 R protein with sufficient specificity in kidney tissue by Western blot.
Our immunohistochemical staining studies revealed apparent AT 1 R localization in the renal vasculature and proximal and distal tubules. However, identical staining patterns were observed when kidneys from mice lacking both AT 1 R subtypes (AT 1AB KO) were used. The positive AT 1 R immunostaining in the renal microvasculature of the AT 1AB KO kidneys was unexpected because these tissues lack renal vasoconstrictor responses to angiotensin II in in vitro and in vivo. 13, 14 Additionally, the apparent positive AT 1 R immunostaining was also observed in the liver vasculature of AT 1AB KO mice, indicating that the nonspecific positive antibody staining observed in the vascular smooth muscle of the AT 1AB KO is not restricted to the kidney. The identity of the proteins recognized by these antibodies remains elusive. We conducted immunoprecipitation of kidney homogenates (using antibodies 1 and 2) followed by mass spectrometry and were unable to identify either the AT 1 R or any other protein in the 41-kDa range. Two possibilities may explain these inconclusive results: (1) the antibodies are not suitable for immunoprecipitation experiments; and (2) the nonspecific protein has yet to be reported and, therefore, does not exist in the current peptide database. Nonetheless, despite our inability to identify the specific protein or proteins identified by these antibodies, the cumulative results from our studies provide compelling evidence that this protein is not the AT 1 R.
We were confident that these findings were intrinsic to the antibodies and not to the presence of AT 1 R in our knockout lines because we verified the absence of AT 1 R mRNA expression and functional responses to angiotensin II in randomly selected mice from our colony. Based on the strategy of gene disruption used to generate our KO mice 14, 15 where many stop codons were introduced into the early portions of the coding sequence of each gene, it is theoretically possible that very small, truncated forms of the receptors might be generated. However, it is highly unlikely that these protein fragments would reach the cell surface. Moreover, if present, they should appear as unique bands in the knockout mice with sizes substantially smaller than that predicted for the native AT 1 R protein. 14, 15 We used HEK cells over-expressing AT 1A receptors to test the antibodies again. Our confocal fluorescence images in living HEK cells show proper plasma membrane expression of the AT 1A receptor. In addition, AT 1A -mCherry fluorescence was not significant in the endoplasmic reticulum, indicating that processed AT 1A R proteins were properly sorted to the Golgi apparatus for further secretion, as shown by colocalization with the marker for this organelle. These findings indicate that HEK cells are able to transcribe, translate, and normally sort the AT 1A R, which localizes normally to the plasma membrane. Accordingly, we used HEK cells transfected with the AT 1A R-His plasmid. Using an anti-His antibody, we detected distinct amounts of His-tagged AT 1A R proportional to the amount of DNA transfected under each experimental condition. Bands of molecular weights in the ≈39-kDa and ≈65-kDa range were detected only in cells transfected with the AT 1A -His plasmid (red boxes on Figure 5B ). A single band at ≈51 kDa was present in all samples, including the mocktransfected cells, and likely represents endogenous His proteins expressed by HEK cells (marked with an asterisk on Figure 5B ). Nevertheless, the ≈39-kDa band is consistent with the nonglycosylated form of the AT 1 R 12 even though one may question the apparent molecular weight of AT 1 R "monomer" because this band appears to be slightly smaller than the predicted 41 kDa mass of this protein. This small apparent difference in size could be accounted for by an altered migration velocity due to the positively charged histidines added to the carboxyl-terminal tail. Furthermore, the multiple bands apparent at ≈39 kDa could also be proteolytic degradation products of the AT 1 R protein. Additionally, although the multiple banding at ≈65 kDa is consistent with the different degrees of AT 1 R glycosylation reported for the rat kidney, 16 it is also possible that these bands represent ubiquitinated receptor which is the mechanism whereby the AT 1 R is degraded. Nevertheless, in contrast to the anti-His antibody, these bands were not identified by any of the anti-AT 1 R antibodies. Although we do not observe specific reactivity of the antibodies to AT 1 R protein expressed at high levels in HEK cells, the failure of the antibodies to detect the AT 1 R in Western blots does not appear to be an issue of insufficient sensitivity. It is important to note that the nonspecific bands recognized by the anti-AT 1 R antibodies in HEK cells are different in number and size compared with those observed in the kidney tissues (Figure 2 ), which provides additional evidence for the lack of specificity of these antibodies. Although the inability of the commercial antibodies to recognize the AT 1 R protein could be explained by potential masking of the epitope by the His tag, we believe this is unlikely to occur because of the denaturing conditions used to unfold the proteins in our Western blotting technique. Additionally, the His tag is attached at the carboxy terminus region of the protein, and at least 2 of the antibodies tested are raised against the amino terminus sequence.
Other investigators attempted to generate custom-made antibodies without success. The Daugherty laboratory 8 generated several antisera against potential new antigenic sites within the AT 1 R receptor, and they were not able to demonstrate any specific interaction to the AT 1A or AT 1B receptors by either Western blotting or immunostaining of tissue sections. In a different report by Hoffmann et al, 17 investigators generated antibodies using the last 20 amino acids of the carboxy terminus tail of each AT 1A and AT 1B receptors. These antibodies yielded bands of different molecular mass in neural cells compared with mammalian tissues. Although these bands were absent when preincubating the antibodies with the immunizing synthetic peptides, this strategy alone is insufficient to demonstrate specificity for the intact receptor protein, and thus the specificity of such antibody remains elusive. Finally, using a monoclonal antibody (6313/G2) raised against and N-terminal peptide (residues 8-17), we previously localized the AT 1 R protein in renal vascular smooth muscle cells, proximal tubule, and more distal nephron segments in kidneys of adult rats. 16, 18 The specificity of this antibody was confirmed by Western blotting of COS-7 cells transfected with an AT 1 R-expressing plasmid. 19 Thus, it is possible that identification of the AT 1 R by antibody-based techniques is suitable for rat but not mouse tissues. In contrast, the Bernstein laboratory raised a polyclonal antibody against N-terminal peptide residues 15-24, which stained mainly vascular smooth muscle cells, brush border, and thick ascending limbs. 20 Unlike our report, this antibody failed to demonstrate immunoreactivity in distal collecting ducts. The origin of this discrepancy is still unknown, but it may be explained by some degree of antibody cross-reactivity. Unfortunately, the identity of the peptide being recognized in such studies has not been verified likely because AT 1 KO mice were not available at the time.
Perspectives
We report here that commercially available antibodies are erroneous tools to detect the AT 1 R protein. Generation of highly specific antibodies for G protein-coupled receptors has reportedly been difficult, [21] [22] [23] [24] [25] [26] and the reasons behind this are yet to be understood. One explanation is potential differences in structure and charge between the glycosylation (naturally carried in the AT 1 R) and the synthetic peptides used when raising these antibodies. Successful strategies to generate reliable anti-AT 1 R antibodies are urgently needed. Investigators should use alternative methods such as ligandbinding, 1 epitope-tagging, 27 Northern blot, 28 or quantitative real-time-polymerase chain reaction when studying the biology of AT 1 R. Interpretations of previously published work relying solely on quantitative and qualitative assessments of the AT 1 R protein using these antibodies should be viewed with extreme caution.
What Is New?
• Antibody-based detection of AT 1 R is unreliable as a result of the lack of specificity of commercial antibodies that recognize proteins different than the AT 1 R.
What Is Relevant?
• The AT 1 R mediates the hypertensive actions of angiotensin II. Understanding AT 1 R protein tissue distribution, abundance, and interaction with other molecules is crucial to elucidate the pathophysiology of cardiovascular and renal diseases and develop new pharmacologic tools for their treatment.
• Many investigators have published studies using these unreliable antibodies.
• Caution must be used when interpreting such reports and designing experimental approaches to understand the biology of these receptors.
Summary
Our studies indicate that commercially available antibodies may not always be suitable for detecting AT 1 R protein. Inclusion of appropriate positive and negative controls is essential when using antibody-based techniques. Investigators should be wary of using these tools when designing new experimental approaches to understand the biology and pathophysiology of AT 1 receptors.
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